Martin Sebastian Allen-Auerbach MD
Associate Professor, Molecular & Medical Pharmacology, UCLA School of Medicine
Join to View Full Profile
200 UCLA Medical Plz Ste B114Los Angeles, CA 90095
Phone+1 310-794-1005
Fax+1 310-267-0227
Dr. Allen-Auerbach is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Nuclear Medicine, 2002 - 2003
New York Downtown HospitalResidency, Internal Medicine, 1999 - 2002
University of Vienna Faculty of MedicineClass of 1995
Certifications & Licensure
CA State Medical License 2002 - 2028
American Board of Nuclear Medicine Nuclear Medicine
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2016-2017
Clinical Trials
Publications & Presentations
PubMed
- Phase 2 Prospective Trial of Retreatment with [Lu]Lu-PSMA-617 Molecular Radiotherapy for Metastatic Castration-Resistant Prostate Cancer-RE-LuPSMA.John Nikitas, Adrien Holzgreve, Jesus Juarez, Koichiro Kimura, Stephanie Lira
Journal of Nuclear Medicine. 2026-02-12 - Noninvasive in vivo deoxycytidine kinase (dCK)-PET identifies tumor-draining lymph nodes upon immune checkpoint inhibitor therapy.Cécile Philippe, Jonathan Cotton, Gregory D Bowden, Simone Pöschel, Philipp Knopf
Npj Imaging. 2026-01-06 - 2 citationsLu-Prostate-Specific Membrane Antigen Neoadjuvant to Stereotactic Ablative Radiotherapy for Oligorecurrent Prostate Cancer (LUNAR): An Open-Label, Randomized, Controll...Amar U Kishan, Luca F Valle, Holly Wilhalme, Carol Felix, Rejah Nabong
Journal of Clinical Oncology. 2025-12-20
Press Mentions
UCLA Health Earns Comprehensive Center of Excellence Designation for Radiopharmaceutical Therapy as Work Continues on New FacilityJune 29th, 2022
Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical TrialJune 1st, 2019
Other Languages
- German, Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
